While the use of artificial intelligence systems is expanding in oncology, ethical issues including biases introduced in care delivery and uneven access to technology raise concerns about whether some patients may be left behind
In a study, a machine learning approach outperformed cancer-specific models and revealed universal biomarkers to guide end-of-life care decisions
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.
Artificial intelligence has entered drug discovery and development supporting target identification and validation, but challenges remain
ESMO now welcomes members from other disciplines to support and expedite the digital transformation of cancer care
A system integrating computer tomography scans and pathological markers offers promise to personalise adjuvant therapy
Experts’ discussions during ESMO Breast 2025 provided an overview on promises and challenges in the field
Progress in artificial intelligence tools is opening-up novel modalities to provide education and doctor-patient communication
While AI tools have shown promise in reducing false positives and aiding radiologists, large prospective trials are now exploring how technology should be integrated in screening programmes
A new ESMO systematic review maps AI’s growing role in pathology and oncology, as well as challenges in its implementation due to infrastructure, regulatory framework and human factors
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.